Skip to main content

Aclaris Therapeutics, Inc 10-Q for FY2026 Q3

Aclaris Therapeutics, Inc. (ACRS)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

Aclaris Therapeutics, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

ATI-052 produced positive Phase 1b results in atopic dermatitis and asthma, while Aclaris Therapeutics reported a $59.8 million net loss for the nine months ended September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.48M
down 55.1% from $3.3M a year earlier
Net loss
$18.51M
compared with a net loss of $14.61M a year earlier
Diluted EPS
-$0.12
compared with -$0.12 a year earlier